StreetAlpha.app
Home › Stocks › OTLK

Outlook Therapeutics, Inc. (OTLK)

Healthcare
$0.36
▼ −8.94%
LAST CLOSE · NOV 17

Outlook Therapeutics develops ONS-5010/LYTENAVA, an eye treatment based on bevacizumab for wet macular degeneration. It last closed at $0.36 on Nov 17, down 8.94% on the day. OTLK reports earnings on Fri, Dec 18, 2026.

AI Auto Pilots
Is OTLK in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$61.1M
EPS (diluted)
−$0.70
Valuation
Market cap
$87.8M
243.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$11.2M
At Jun 30
Shareholder equity
−$10.4M
Shares outstanding
243.4M
At Aug 14
Fiscal year endsSeptember
ExchangeNasdaq
Financials history
FY2021: −$53.2M−$53.2MFY2021FY2022: −$66.1M−$66.1MFY2022FY2023: −$59.0M−$59.0MFY2023FY2024: −$75.4M−$75.4MFY2024FY2025: −$62.4M−$62.4MFY2025

From OTLK's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 18). Last 12 months adds up the four latest quarters.

Next report
Dec 18
2026 · Time not announced
Consensus EPS forecast
-$0.08
$1.8M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated OTLK in the past 90 days, not enough for a consensus
Average 12-month target
$10.50
▲ 2811.8% upside

Based on 1 analyst who set a price target on OTLK in the past 90 days. The average target is $10.50, with a high of $10.50 and a low of $10.50, compared with the last close of $0.36.

$0$3$7$11PAST 17 TRADING DAYS12-MONTH TARGETSHIGH $10.50AVG $10.50LOW $10.50May 26LAST CLOSE+12 MO$0$3$7$11PAST 17 DAYSTARGETSHIGH $10.50AVG $10.50LOW $10.50May 26LAST CLOSE+12 MO
Highest target$10.50
Average target$10.50
Lowest target$10.50
Latest rating changes
Ascendiant CapitalTarget raised
Sep 11Buy$10 → $10.50
HC Wainwright & Co.Maintained
Jul 27Hold$1.60
BTIGUpgrade
Jul 27Buy$4
Ascendiant CapitalMaintained
Jun 11Buy$10
DateFirmActionRatingPrice target
Sep 11Ascendiant CapitalTarget raisedBuy$10 → $10.50
Jul 27HC Wainwright & Co.MaintainedHold$1.60
Jul 27BTIGUpgradeBuy$4
Jun 11Ascendiant CapitalMaintainedBuy$10
Loading…

Technical Analysis

OTLK · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 31% below its 20 day and 53% below its 50 day average. It is 83% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot S1 at $0.34, and the nearest resistance the Pivot at $0.37.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 11.8%/day
Key levels
$2.5452 week high+605.6%
$0.82100 day average+127.8%
$0.66200 day average+83.3%
$0.5550 day average+52.8%
$0.50Swing high (Nov 11)+38.9%
$0.4720 day average+30.6%
$0.38Pivot R1+5.6%
$0.37Pivot+2.8%
$0.36Last close
$0.34Pivot S1−5.6%
$0.1652 week low−55.6%
Indicators
RSI (14)27.91Oversold below 30Oversold
MACD-0.04Below its signal lineBearish
Stochastic6.0Near the bottom of its rangeOversold
ADX (14)26.1Trending down
Williams %R-94.4Oversold below −80, overbought above −20Oversold
CCI (20)-175.1Oversold below −100, overbought above 100Oversold
Rate of change−21.6%Change over 10 sessionsBearish
ATR (14)$0.04Typical daily range, 11.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OTLK

What happened before

See how OTLK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OTLK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OTLK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OTLK in the last 90 days.

Loading…

See today’s whale options flow across the market →

OTLK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲48 buying vs 24 selling
  • ▲Held by funds +17.7 pts
  • ▲Funds holding +12
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8270+17.1%
In funds' top 1010–
Held by funds26.1%8.4%+17.7 pts
New / increased26 / 2227 / 20+2.1%
Reduced / sold out11 / 137 / 13+20.0%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OTLK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OTLK is in one of them and how their past OTLK trades turned out.

OTLK in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OTLK in an article yet. Here's the latest on the wider market.

About Outlook Therapeutics

Outlook Therapeutics is a biopharmaceutical company based in Iselin, New Jersey. Its main product is ONS-5010/LYTENAVA, an eye treatment based on bevacizumab, an antibody first approved for cancer and adapted for use in the eye. It is used to treat wet macular degeneration, a condition that can damage central vision. The product is approved in the European Union and the United Kingdom, where the company sells it directly, and it is under review in the United States.

Headquarters
Iselin, NJ